Citigroup maintains SpyGlass Pharma at Buy, raises price target to $45 from $42

Citigroup kept its Buy rating on SpyGlass Pharma and increased its price target to $45 from $42, suggesting a 36.9% upside from the Nov 13 close of $32.88.

Original reporting
Published Nov 13, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Citigroup maintains SpyGlass Pharma at Buy, raises price target to $45 from $42 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The rating lift could trigger short covering and buying interest.

02

Market read

Analyst upgrade provides a fresh catalyst for SGPH, potentially driving short‑term price appreciation.

03

What to watch

The upgrade does not reflect any new clinical data; it may be based on broader market sentiment.

Relevance 7/10Novelty 7/10Timing: immediate

Background

SpyGlass Pharma is a micro‑cap biotech whose stock trades around $33.

Market effects

Positive signal for small‑cap biotech sector as analysts raise expectations.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

Some investors may wait for actual earnings data before acting on an analyst target.

Key entities

  • Citigroup

    Upgraded SpyGlass Pharma to Buy and raised price target.

Related articles

$SGPHighAI 8/10

Stifel raises SpyGlass Pharma stock price target to $44

Stifel raised its price target for SpyGlass Pharma (NASDAQ:SGP) to $44 from $42, maintaining a Buy rating. The stock has gained 40% in six months but declined 9.8% recently, trading at $33.32. The update follows a conference and Q3 earnings, with a higher probability of success for BIM-DRS. The company also reported positive trial data and acquired Advanced Vision Science for $13M.

$SGPMedAI 8/10

SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates • Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatopro

$SGPMedAI 8/10

SpyGlass Pharma’s BIM-IOL Cuts IOP 37% at 4 Years, 86% Drop-Free

SpyGlass Pharma (SGP) reported 4-year trial data for its BIM-IOL System, showing a 37% mean reduction in intraocular pressure (IOP) and no adverse events. The trial involved 21 patients with glaucoma or ocular hypertension. The company plans to pursue a 505(b)(2) NDA with the FDA, with Phase 3 trials ongoing. The BIM-IOL System is designed to deliver bimatoprost for up to 7 years from a single implant during cataract surgery.

$SGPMedAI 8/10

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System Groundbreaking 4-year safety and efficacy results: • 37% reduction in mean intraocular pressure (IOP) across all dose groups • 86% of patients remained off all t